Elvia Cowan, SVP, FINANCE at Vaxcyte, Inc. (PCVX), sold 23,680 shares at $74.90 ($1.8M) on 2024-03-01, disclosed to the SEC on 2024-03-04.
Scheduled sale ($1.8M) by SVP, FINANCE under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.08 | 2,322 | $170K | 9.7% |
| 2 | $73.08 | 2,322 | $170K | 9.7% |
| 3 | $73.69 | 4,455 | $328K | 18.7% |
| 4 | $73.69 | 4,455 | $328K | 18.7% |
| 5 | $74.90 | 4,901 | $367K | 20.9% |
| 6 | $74.90 | 4,901 |
| $367K |
| 20.9% |
| 7 | $71.55 | 324 | $23K | 1.3% |
| Total | $74.04 avg | 23,680 | $1.8M | 100% |
| Filing → |
| PCVX | SELL | 2026-03-18 | $210K | — | Filing → |
| PCVX | SELL | 2026-03-11 | $293K | — | Filing → |
| PCVX | SELL | 2025-12-29 | $1.1M | — | Filing → |